SAB Biotherapeutics, Inc. (SABS) - Dilution Analysis

10-Q filing | 76.5M shares outstanding

10-K filing | 51.0M shares outstanding

S-3 filing: The filing is an S-3 form indicating the company may offer and sell up to $300,000,000 of any combination of common stock, preferred stock, or debt securities from time to time.

S-3 filing: This prospectus relates to the offer and resale, from time to time, by the selling stockholders of up to 250,000,000 shares of the Company's common stock.

10-Q filing | 10.4M shares outstanding

8-K filing: SAB Biotherapeutics, Inc. entered into a securities purchase agreement to issue and sell 1,000,000 shares of Series B Convertible Preferred Stock and warrants to purchase Preferred Stock for gross proceeds of approximately $175 million. ($175.0M proceeds)

10-Q filing | 9.3M shares outstanding

10-K filing | 9.3M shares outstanding

10-Q filing | 9.3M shares outstanding

10-Q filing | 9.3M shares outstanding

10-Q filing | 9.2M shares outstanding

10-K filing | 9.2M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 52,406,002 → 9

S-3/A filing: This S-3/A filing registers for resale up to 344,626,967 shares of common stock by selling stockholders, including shares issuable upon conversion of preferred stock and exercise of warrants.

10-Q filing | 52.4M shares outstanding

S-3 filing: This prospectus relates to the offer and resale, from time to time, by the selling stockholders of up to 412,698,389 shares of the Company's common stock.

8-K filing: SAB Biotherapeutics, Inc. entered into a securities purchase agreement to issue and sell 7,500 shares of Series A-1 Convertible Preferred Stock for $7.5 million, along with warrants to purchase Series A-3 Preferred Stock. ($7.5M proceeds)

10-Q filing | 50.4M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling securityholder identified in this prospectus of up to 1,916,894 shares of our common stock.

POS AM filing: This prospectus relates to the resale by the selling securityholder identified in this prospectus of up to 2,216,894 shares of our common stock.

10-Q filing | 50.4M shares outstanding

S-3 filing: The company intends to offer and sell up to $50,000,000 of any combination of common stock, preferred stock, debt securities, warrants, rights or units from time to time.

S-3 filing: SAB Biotherapeutics, Inc. files an S-3 form relating to the resale of up to 300,000 shares of common stock by the selling securityholder.

10-K filing | 50.4M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 14,726,754 shares of common stock, including shares issuable upon the exercise of warrants, by selling stockholders.

POS AM filing: This prospectus relates to the issuance of up to 5,958,600 shares of our common stock upon exercise of warrants and the offer and sale from time to time of up to 9,960,241 shares of Common Stock by the selling securityholders.

8-K filing: SAB Biotherapeutics, Inc. completed a private placement offering, selling 7,363,377 shares of common stock and warrants to purchase up to 7,363,377 shares at a combined price of $1.08 per share and accompanying warrant, resulting in gross proceeds of approximately $8.0 million. ($8.0M proceeds)

10-Q filing | 43.0M shares outstanding

S-1 filing: S-1 filing for shares of common stock and warrants to purchase common stock.

10-Q filing | 43.0M shares outstanding

10-Q filing | 43.1M shares outstanding

POS AM filing: This is a POS AM filing for the issuance of common stock upon exercise of warrants and the offer and sale of common stock by selling securityholders.

10-K filing | 43.0M shares outstanding

S-1 filing: S-1 filing for the issuance of up to 14,434,301 shares of common stock and up to 5,958,600 shares of common stock issuable upon exercise of warrants.

10-Q filing | 43.5M shares outstanding

8-K filing: Big Cypress Acquisition Corp. entered into a Forward Share Purchase Agreement with Radcliffe SPAC Master Fund, L.P., where Radcliffe may sell up to 1,390,000 shares of the Company's common stock to the Company at $10.10 per share, subject to certain conditions.

8-K filing: Big Cypress Acquisition Corp. amended its business combination agreement with SAB Biotherapeutics, Inc., modifying terms for the merger and earnout shares.

10-Q filing | 14.8M shares outstanding

10-Q filing | 14.8M shares outstanding

10-K filing | 14.8M shares outstanding

8-K filing: Big Cypress Acquisition Corp. consummated its initial public offering of 11,500,000 units at $10.00 per unit, generating gross proceeds of $115,000,000, and simultaneously consummated a private placement of 417,200 units at $10.00 per unit, generating total proceeds of $4,172,000. ($119.17M proceeds)

S-1/A filing: This S-1/A filing describes an offering of 10,000,000 units at $10.00 per unit, each unit consisting of one share of common stock and one half of one redeemable warrant.

S-1/A filing: S-1/A filing for a blank check company offering 10,000,000 units at $10.00 per unit, each unit consisting of one share of common stock and one half of one redeemable warrant.

S-1 filing: Initial public offering of units, each consisting of one share of common stock and one half of one redeemable warrant, for a blank check company targeting the life sciences industry.